The Technical Analyst
Cyclerion Therapeutics [CYCN]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Cyclerion Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.46% $0.540
Last updated: 16 May 2022 @ 10:14 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 23.45 mill |
| EPS: | -1.319 |
| P/E: | 0.000 |
| Earnings Date: | Feb 24, 2022 |
| SharesOutstanding: | 43.45 mill |
| Avg Daily Volume: | 0.119 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| True Range Average |
|---|
|
+/- $0.0990 ( +/- 17.52%) Range: 0.466 - 0.664 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-01-20 | Busch Andreas | Buy | 135 000 | Employee Stock Option (Right to Buy) |
| 2022-01-20 | Gjino Anjeza | Buy | 135 000 | Employee Stock Option (Right to Buy) |
| 2022-01-20 | Hecht Peter M | Buy | 430 000 | Employee Stock Option (Right to Buy) |
| 2022-01-20 | Hecht Peter M | Buy | 52 950 | Employee Stock Option (Right to Buy) |
| 2022-01-20 | Gault Cheryl | Buy | 135 000 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 83.93 |
| Last 100 transactions |
| Buy: 11 918 854 | Sell: 15 650 431 |
Forecast:
11:51 - $0.560
Live Trading Signals (every 1 min)
Forecast
1: 10:21 - $0.540
Forecast 2: 11:11 - $0.556
Forecast 3: 11:51 - $0.560
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.540 (-4.46% ) |
| Volume | 0.0252 mill |
| Avg. Vol. | 0.119 mill |
| % of Avg. Vol | 21.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYCN
114 Signals | Accuracy: 16.67% | Accuracy Buy: 12.28% | Accuracy Sell: 21.05%
Avg return buy: -1.68 % | Avg return sell: 0.93 %
$1 invested is now $0.37 or -62.89% since 21-04-22
| Date | Signal | @ | Closed | % | May 16 - 09:42 | sell | $0.546 | N/A | Active |
|---|---|---|---|---|
| May 16 - 09:33 | buy | $0.570 | $0.560 @ May 16 - 09:41 | -1.82% |
| May 13 - 13:00 | sell | $0.570 | $0.576 @ May 13 - 14:33 | 0.98% |
| May 13 - 12:55 | buy | $0.571 | $0.570 @ May 13 - 12:59 | -0.21% |
| May 13 - 12:48 | sell | $0.570 | $0.571 @ May 13 - 12:55 | 0.19% |
| May 13 - 12:30 | buy | $0.570 | $0.570 @ May 13 - 12:47 | 0.00% |
| May 12 - 12:44 | sell | $0.608 | $0.570 @ May 13 - 12:28 | -6.27% |
| May 12 - 11:43 | buy | $0.627 | $0.608 @ May 12 - 12:43 | -3.05% |
| May 12 - 11:39 | sell | $0.570 | $0.627 @ May 12 - 11:42 | 10.05% |
| May 12 - 11:27 | buy | $0.556 | $0.570 @ May 12 - 11:38 | 2.48% |
CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2022-02-23 08:00:00 - Press Release
Cyclerion Therapeutics And Ariana Pharma Announce An Artificial Intelligence-driven Precision Medicine Collaboration
Collaboration to identify patient-selection biomarkers for cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment collaboration to identify patient-selection biomarkers for cyclerion's investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
2022-01-26 08:00:00 - Press Release
Cyclerion Therapeutics Announces Initiation Of Patient Dosing In Cy6463 Phase 2a Study In Alzheimer's Disease With Vascular Pathology
Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition
2021-11-11 17:32:00 - Press Release
Cyclerion Therapeutics To Participate In Jefferies London Healthcare Conference
Cambridge, mass., nov. 11, 2021 (globe newswire) -- cyclerion therapeutics, inc. (nasdaq: cycn), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the jefferies london healthcare conference on nov. 16th to 18th, 2021. a pre-recorded corporate presentation will be available on-demand beginning on thursday, nov. 18 and will remain available for 30 days in the investor section of the cyclerion website. management will be available for one-on-one meetings and investors may request a meeting through jefferies.
2021-09-22 08:00:00 - Press Release
Cyclerion Announces Publication Of Preclinical Data Demonstrating Reduction In Neuroinflammation By Brain-penetrant Sgc Stimulator
Company developing lead sgc stimulator, cy6463, in multiple cns diseases associated with cognitive impairment company developing lead sgc stimulator, cy6463, in multiple cns diseases associated with cognitive impairment
2021-08-23 17:00:00 - Press Release
Cyclerion Therapeutics To Present At Annual Biomarkers For Alzheimer's Disease Summit
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of alzheimer's disease therapies presentation to highlight the potential of early clinical assessment of biomarkers to drive development of alzheimer's disease therapies
Latest News
2021-12-15 11:35:17 - Zacks Investment Research
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2021-10-26 16:29:42 - Seeking Alpha
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.
2021-10-24 14:30:00 - PennyStocks
Trending Penny Stocks to Buy Now? 5 to Watch This Week
Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
2021-09-22 08:00:00 - GlobeNewsWire
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment
2021-08-23 17:00:00 - GlobeNewsWire
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies
2021-07-29 17:00:00 - GlobeNewsWire
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive impairment
2021-07-22 16:30:00 - GlobeNewsWire
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics
2021-07-09 06:14:09 - Benzinga
Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers
Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerion's CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment.
2021-07-08 19:22:00 - PRNewsWire
Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership
BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.
2021-07-08 16:30:00 - GlobeNewsWire
Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment Beacon Biosignals and Cyclerion to extend and expand partnership on data collection and analytics strategy to facilitate development of Cyclerion investigational therapeutics for neurological diseases associated with cognitive impairment